CTD stands for Common Technical Document, which is a standardized format for organizing and presenting data for regulatory submissions in the pharmaceutical industry. It was developed by the International Conference on Harmonisation (ICH) to streamline the drug approval process across different regulatory agencies worldwide.
The CTD structure consists of five modules that cover quality, safety, and efficacy information for drug products. This harmonized format facilitates efficient review by regulatory authorities and promotes consistency in drug applications across different countries and regions.
The CTD is crucial in clinical research as it provides a standardized framework for organizing and presenting data from drug development programs. This standardization enhances the efficiency of regulatory reviews, facilitating faster and more consistent drug approval processes across different regulatory agencies worldwide.
Furthermore, the CTD format ensures that all necessary information is included in regulatory submissions, reducing the likelihood of delays due to incomplete or poorly organized data. By adopting this globally recognized structure, pharmaceutical companies can streamline their development and submission processes, potentially accelerating the time-to-market for new therapies.
We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…
The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…
Copyright @ 2026 Axcellant